A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

29 August 2025 (09:09 - 09:27)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Thomas Fretz

Indiana University School of Medicine, Indianapolis (United States of America)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Professor D. Capodanno (Catania, IT)

Presentation thumbnail

Impact of antiplatelet pretreatment on stent thrombosis in patients undergoing PCI in real world practice: insight France PCI registry

Doctor G. Range (Chartres, FR)

Abstract Slides Video

Presentation thumbnail

Aspirin reloading before percutaneous coronary intervention on chronic aspirin therapy: reduced early ischemia without bleeding trade-off

Doctor W. Dai (Tianjin, CN)

Abstract Slides Video

Presentation thumbnail

12- vs. 1-month DAPT: comparative outcomes after aspirin cessation with HT supreme stent

Doctor T. Tsai (Galway, IE)

Abstract Slides Video

Access the full session

Session thumbnail

Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

The Event

Event poster

ESC Congress 2025

29 August 2025 09:09 CET

You may be interested in

Congress Presentation

A very short duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

Congress Presentation

Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention

Congress Presentation

A shorter duration of dual-antiplatelet therapy for percutaneous coronary intervention following acute coronary syndrome: a meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources